ObjeCtivesTo examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of heart failure or hospital admission for heart failure in patients with type 2 diabetes. DesignSystematic review and meta-analysis of randomised and observational studies. Data sOurCes

BackgroundThe clinical decision support system(CDSS) has potential to improving medication safety. However, the effects of the intervention were conflicting and uncertain. Meanwhile, the reporting and methodological quality of this field were unknown.ObjectiveThe aim of this overview is to evaluate the effects of CDSS on medication safety and to examine the methodological and reporting quality.MethodsPubMed, Embase and Cochrane Library were searched to August 2015. Systematic reviews (SRs) investigating the effects of CDSS on medication safety were included. Outcomes were determined in advance and assessed separately for process of care and patient outcomes. The methodological quality was assessed by Assessment of Multiple Systematic Reviews (AMSTAR) and the reporting quality was examined by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).ResultsTwenty systematic reviews, consisting of 237 unique randomized controlled trials(RCTs) and 176 non-RCTs were included. Evidence that CDSS significantly impacted process of care was found in 108 out of 143 unique studies of the 16 SRs examining this effect (75%). Only 18 out of 90 unique studies of the 13 SRs reported significantly evidence that CDSS positively impacted patient outcomes (20%). Ratings for the overall scores of AMSTAR resulted in a mean score of 8.3 with a range of scores from 7.5 to 10.5. The reporting quality was varied. Some contents were particularly strong. However, some contents were poor.ConclusionsCDSS reduces medication error by obviously improving process of care and inconsistently improving patient outcomes. Larger samples and longer-term studies are required to ensure more reliable evidence base on the effects of CDSS on patient outcomes. The methodological and reporting quality were varied and some realms need to be improved.

Summary Childhood obesity increases the risk of adulthood obesity and is associated with other adverse health outcomes later in life. It may be influenced by environmental characteristics of neighborhoods where children live, particularly dietary supply–related environmental factors. This study aimed to systematically review the evidence on the association between access to convenience stores and childhood obesity. We searched and filtered relevant literature in PubMed, Embase, Web of Science, and Cochrane Library published before 1 January 2019. Data on the basic characteristics of studies, measures of access to convenience stores, and associations of convenience stores with weight‐related behaviors and outcomes were extracted from 41 included studies. In general, the density of and proximity to convenience stores in children's residential and school neighborhoods were positively associated with unhealthy eating behaviors. However, their associations with children's weight status varied significantly by regions. The association between convenience store access and children's weight status was found to be negative in Canada, rather mixed in the United States and the United Kingdom, and not significant in East Asia. We suggest future research to clearly define the convenience store, better measure the access to convenience store, and also measure children's journey and food purchasing and consumption behaviors, to explain pathways from convenience store access to childhood obesity for designing effective interventions and policies.

Summary Childhood obesity is one of the most pressing public health issues nowadays. The environmental factors have been identified as potential risks for obesity, as they may influence people's lifestyle behaviours. Lack of access to supermarkets that usually provide healthy food options has been found to be a risk factor for childhood obesity in several studies. However, findings remained inconclusive. We aimed to systematically review the association between access to supermarkets and childhood obesity. A literature search was conducted in the Cochrane Library, PubMed, Web of Science, and Embase for studies published before 1 January 2019. Twenty‐four studies conducted in four countries were identified, from which data on the basic characteristics of studies and participants, measures of access to supermarkets, and associations between access to supermarkets and weight‐related behaviours and outcomes were extracted. The median sample size was 1858 participants. Half of the included studies indicated a negative association, one fourth reported a positive association, and the remaining one fourth did not find a significant association. Better designed studies are necessary to achieve a robust understanding of this epidemiological relationship in the future.

Alpha-glucosidase inhibitors (AGIs) was reported to be associated with several rare adverse hepatic events, but with inconsistent results. We aimed to investigate the risk of hepatotoxicity associated with the use of AGIs in patients with type 2 diabetes mellitus (T2DM), and performed a systematic review and meta-analysis. Fourteen studies (n = 2881) were eligible, all of which were RCTs. Meta-analysis of data regarding elevation of more than 3-fold the upper limit of normal (ULN) of AST and ALT showed statistically significant differences between AGIs treatment versus control (OR 6.86, 95% CI 2.50 to 18.80; OR 6.48, 95% CI 2.40 to 17.49). Subgroup analyses of elevation of more than 1.8-fold ULN of AST and ALT by dose of AGIs showed differential effects on AST and ALT (AST: OR 0.38 vs 7.31, interaction P = 0.003; ALT: OR 0.32 vs 4.55, interaction p = 0.02). Meta-analysis showed that AGIs might increase the risk of hepatotoxicity, and higher dose appeared to be associated with higher risk of hepatotoxicity. However, the evidence is limited with surrogate measures (i.e. ALT and AST), and no clinically important adverse events were observed.Alpha-glucosidase inhibitors (AGIs) are commonly used oral hypoglycemic drugs, especially in the patient population from East Asia 1-3 . The guideline of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommended the use of AGIs as a potentially first-line agent or in combination with other antihyperglycemic drugs 4 . AGIs has proven similarly efficacious as other commonly used antidiabetes agents [5][6][7] . A recent large trial 1 showed that acarbose is similar to metformin in terms of efficacy, and supports a viable choice for initial therapy in patients with newly diagnosed type 2 diabetes. Additionally, AGIs do not increase body weight, rarely cause hypoglycemia; and have minimal drug-drug interactions 1,7,8 . Meanwhile, AGIs was reported to be associated with several rare adverse hepatic events 9-11 and increase liver enzyme levels [12][13][14][15][16][17][18] . The causal relationship, however, has not been established 9 , and the magnitude of effect on the increase of liver enzyme levels remains unclear. Because these issues are often treated as adverse effects issues, and the hepatic adverse events, if any, are usually rare, individual trials are not adequate to address these important clinical questions. A meta-analysis -in which multiple studies are pooled -may offer opportunity to detect a small but clinically important difference.Thus, we carried out a systematic review of randomized controlled trials and observational studies to assess the association between hepatotoxicity and AGIs. We hypothesized that hepatotoxicity would be more frequently manifested in AGIs as opposed to no use. Figure 1 showed the study selection process. We acquired 5,318 reports. After title and abstract screening, 178 were potentially eligible (including 159 potentially relevant RCTs and 19 potentially relevant observational studies [1...